Time to achieve ITI milestones by treatment arm reported as median (IQR) mo
| . | n . | LD . | n . | HD . | P . |
|---|---|---|---|---|---|
| Phase 1: start of ITI to negative titer | 29 | 9.2 (4.9-17.0) | 31 | 4.6 (2.8-13.8) | .017 |
| Phase 2: negative titer to first normal recovery | 27 | 13.6 (8.7-19.0) | 23 | 6.9 (3.5-12.0) | .001 |
| Phase 3: normal recovery to tolerance | 24 | 15.5 (10.8-22.0) | 22 | 10.6 (6.3-20.5) | .096 |
| . | n . | LD . | n . | HD . | P . |
|---|---|---|---|---|---|
| Phase 1: start of ITI to negative titer | 29 | 9.2 (4.9-17.0) | 31 | 4.6 (2.8-13.8) | .017 |
| Phase 2: negative titer to first normal recovery | 27 | 13.6 (8.7-19.0) | 23 | 6.9 (3.5-12.0) | .001 |
| Phase 3: normal recovery to tolerance | 24 | 15.5 (10.8-22.0) | 22 | 10.6 (6.3-20.5) | .096 |